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Abstract
Background
Optimal management of isolated local recurrence of prostate cancer after primary radiotherapy
remains to be defined. Up-front androgen deprivation therapy (ADT) is widely used but may
adversely affect the quality of life and is essentially a palliative treatment. Local salvage carries
a different side-effect profile and is potentially curative, but it has not been compared to ADT.
Materials and methods
We conducted a propensity-matched analysis of cohorts of men treated with either whole gland
cryotherapy (CRYO) or primary ADT following the diagnosis of locally recurrent prostate
cancer. Our specific objectives were to compare overall survival (OS) and prostate cancer-
specific mortality (PCSM) between CRYO vs. ADT.
Results
After a one-to-one matching, 169 patients from each cohort were included in comparisons.
Median follow-up time was 6.7 years (ADT) vs. 18 years (CRYO). The 10-year PCSM was 18.5%
(ADT) vs. 16.2% (CRYO), which was not statistically different [hazard ratioo (HR): 0.69, 95% CI:
0.36-1.34, p=0.27]. The median OS was 12.3 years (CRYO) versus 10.2 years (ADT) (HR: 0.63,
95% CI: 0.42-0.95, p=0.03).
Conclusions
While PCSM was similar between the two strategies, CRYO was associated with a longer OS
compared to primary ADT. Given the retrospective nature of the trial, these results should be
considered hypothesis-generating, and phase III trials comparing these two options are
required to further explore these findings.
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Introduction
Optimal management of radio-recurrent prostate cancer remains undefined. While some
patients may do well with expectant management, others may benefit from active treatment
due to patient preference or concerns about aggressive biology. For active salvage treatment,
both salvage androgen deprivation therapy (ADT) and local salvage therapies have been
described [1-4]. There is a gap in the literature due to a lack of comparisons between up-front
systemic and local salvage therapies. Literature-based comparisons such as systematic reviews
suffer from selection bias inherent in choosing between these two modalities whereby ADT
might be favored in men with suspected metastatic disease or those who are unfit for local
salvage with ablative salvage therapy, which is offered to fitter men with suspected locally
recurrent disease [5]. To address this knowledge gap, and by acknowledging the potential
selection bias inherent in such comparisons, we undertook a propensity-matched analysis of
local vs. up-front systemic post-radiotherapy salvage using two existing cohorts: an
institutional series of whole gland cryotherapy (CRYO) and the prospective, randomized PR7
trial (NCT00003653) of intermittent vs. continuous ADT (both arms pooled as ADT for this
analysis as the trial demonstrated no significant difference between these schedules) [1,6,7].
Our specific objectives were to compare overall survival (OS) and prostate cancer-specific
mortality (PCSM) between CRYO vs. ADT.
Materials And Methods
CRYO cohort
Outcomes for the CRYO cohort have been previously reported [7]. All CRYO patients were
treated between 1994 and 2004 and had histologic confirmation of local recurrence and
negative restaging studies with CT and bone scan prior to treatment. Patients may have
received ADT prior to treatment, but no patients received routine ADT post CRYO. ADT post
CRYO was started on the basis of physician discretion in the setting of clinical, biochemical, or
histologic evidence of recurrence.
ADT cohort
The Canadian Cancer Clinical Trial Group (CCTG) PR-7 trial enrolled 1,386 men between 1999
and 2005 in a comparison between intermittent and continuous salvage ADT for men with
biochemical failure [rising prostate-specific antigen (PSA) of >3.0] after primary radiation or
radiation after prostatectomy [1]. All patients had negative restaging with CT and bone scan
prior and were at least one year from prior radiotherapy or ADT (if given with primary
radiotherapy). As the outcomes for the men who received intermittent or continuous hormone
therapy were not statistically different, we combined the continuous and intermittent arms in
this prospective randomized trial in generating the propensity-matched ADT cohort for
comparison to CRYO.
Inclusion of participants
Initially, CRYO contained 187 patients and ADT contained 1,386 patients. Patients were
excluded from the analysis if they did not have primary radiotherapy as their initial treatment
or had missing information for any of the baseline factors necessary for the propensity scoring
analysis. Specifically, within CRYO, 15 (8.0%) were excluded because of incomplete histologic
grading and biochemical or outcome data, leaving a total of 172 patients. Within ADT, 159
(11.5%) were excluded because they had prior prostatectomy prior to radiotherapy, 105 (7.5%)
because of missing Gleason Score data, and three (0.2%) because of missing data regarding time
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from original radiotherapy, leaving a total of 1,119 patients.
Baseline factors for propensity-matched analysis
Based on the literature review on important factors of the disease population and the available
data from both data resources, five factors were pre-selected for the propensity scoring analysis:
Gleason Score at diagnosis (<7 vs. 7 vs. >7); time since completion of primary radiotherapy (one
to three vs. >3 years); the history of prior neoadjuvant or adjuvant ADT (yes vs. no); PSA level at
the time of salvage therapy (<4 vs. 4-10 vs. >10 ng/ml); age at the time of salvage therapy (≤70
vs. >70 years old). A comparison of the distribution of these factors by cohort is listed in Table
1.
Variable ADT (n = 169) CRYO (n = 169)
Gleason grade <7 93 100
Gleason grade 7 55 57
Gleason grade >7 21 21
Time since primary RT <3 years 30 23
Time since primary RT >3 years 139 146
PSA at salvage <4 16 19
PSA at salvage 4-10 104 121
PSA at salvage >10 49 29
Age at salvage <70 years 67 77
Age at salvage >70 years 102 92
TABLE 1: Distribution of propensity-matched variables between cohorts after
matching
ADT: androgen deprivation therapy; CRYO: cryotherapy; RT: radiotherapy; PSA: prostate-specific antigen
Outcomes of interest
PCSM was defined as death due to prostate cancer in both populations. Patients who remained
alive or who died of non-cancer or undetermined causes were censored at their time of last
follow-up/death. OS was defined as the time from initial salvage therapy until death from any
cause (as an event) or last follow-up (as a censoring). As was conducted for the progression-free
survival outcome, the patient from the CRYO population with all outcome data missing was
censored on the day after their date of salvage treatment. In order to determine if the use of
ADT prior to CRYO had an effect on these endpoints, we pre-specified subgroup analyses of
CRYO patients who did or did not receive ADT prior to CRYO propensity-matched against the
ADT population.
Propensity scoring analysis
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One-to-one matching was undertaken to select individual ADT matches for the
CRYO population based on propensity scoring analysis conducted using a logistic regression
model with all baseline covariates included to predict treatment with either CRYO or
ADT [6]. Individual matching was completed using an algorithm based on an allowable absolute
difference in the propensity probability of each individual while maximizing the number of
individuals who could be matched. The allowable width for matching was selected to be the
smallest possible value in each situation, which resulted in the complete generation of at least
one match for all CRYO patients. To account for residual variation within a stratum, raw linear
propensity scores were included in the outcomes analysis.
Results
For the matched cohorts, the median follow-up time was 6.73 years (95% CI: 6.23-6.93) among
ADT and 18.65 years (95% CI: 17.95-19.90) among CRYO. Competing risk analysis was used to
compare the PCSM between CRYO and ADT. The cumulative incidence function by treatment
groups is displayed in Figure 1. The 10-year risk of prostate cancer death was 18.5% for patients
in PR7, while it was 16.2% for patients in the CRYO cohort. Overall, there was no difference in
PCSM between ADT and CRYO (HR: 0.76; 95% CI: 0.38-1.48, p=0.41; Fine-Gray regression
model). When raw linear propensity scores were also included in the model to account for
additional variability within propensity score strata, the adjusted PCSM HR for CRYO was 0.69
(95% CI: 0.36-1.34, p=0.27; FIgure 1).
FIGURE 1: Prostate cancer-specific mortality: cumulative
incidence curve comparing deaths from prostate cancer
among CRYO vs. ADT cohort
ADT: androgen deprivation therapy; CRYO: cryotherapy
The median OS time for the CRYO population was 12.33 years (95% CI: 11.02-13.84) versus
10.17 years (95% CI: 9.38-N/A) for ADT (HR: 0.69, 95% CI: 0.45-1.06, log-rank p=0.086; Figure
2). When raw linear propensity scores were also included in the proportional hazard model to
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account for additional variability within propensity score strata, the adjusted HR still favored
CRYO (HR: 0.63, 95% CI: 0.42-0.95, p=0.03; Figure 2).
FIGURE 2: Overall survival: comparison of overall survival
between CRYO and ADT cohorts
ADT: androgen deprivation therapy; CRYO: cryotherapy
OS and PCSM results were examined using propensity matching among the pre-defined subsets
of men who did or did not receive ADT prior to salvage CRYO. Results for these subgroups were
no different from those for the full CRYO population. The median time to ADT institution (for
the CRYO cohort) was approximately 11 years, and the actuarial rate of ADT institution was
90% by 20 years post CRYO. In comparison, the time to develop hormone resistance was
approximately seven years, and the actuarial rate of castrate resistance was approximately 70%
at 10 years.
Discussion
The optimal management of radio-recurrent prostate cancer remains undefined. While some
men may do well with expectant management (lower PSA, longer doubling time), others may
require active treatment due to either patient preference or concerns about more aggressive
biology (higher PSA or shorter PSA doubling time) [8]. ADT is a widely accepted salvage
strategy and carries the advantage of addressing both potential local and distant recurrence of
prostate cancer. Randomized studies have demonstrated the equivalence of continuous and
intermittent ADT approaches [1]. However, concerns about the routine use of ADT remain as
the quality of life may be adversely affected even with intermittent approaches, and medical
complications such as osteoporosis and metabolic syndrome may be triggered [2]. Finally, some
men with isolated local recurrence may be forgoing potentially curative local salvage for an
essentially palliative approach as ADT resistance inevitably develops over time.
Local salvage therapies offer a chance to ablate locally recurrent cancer while avoiding or
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deferring ADT use. A variety of local salvage therapies exist, including salvage prostatectomy,
ablative modalities such as CRYO, high-intensity focused ultrasound, interstitial laser, and
repeat radiotherapy such as brachytherapy (or, more recently, stereotactic external-beam
approaches) [3,4]. In our CRYO cohort, the majority of men eventually required ADT,
suggesting that most men had subclinical metastatic disease in addition to local failure. That
said, the median time to ADT institution was over 10 years, thus avoiding potential toxicity of
ADT for a substantial period.
Despite their availability, these local salvage modalities are infrequently deployed because of
concerns about potential morbidity, variability in access to the expertise and technology for
these specialized salvage therapies, and concerns about futile treatment in the setting of
subclinical metastatic as well as local recurrence. As advanced imaging techniques for prostate
cancer become more common [i.e. prostate-specific membrane antigen-positron emission
tomography (PSMA-PET), multi-parametric magnetic resonance imaging (mpMRI)] and with
the emergence of new therapeutic approaches (improvements in ablative therapies and surgical
techniques), there is renewed interest in local therapies with deferred ADT treatment [9-11].
While there are no randomized trials to compare local salvage modalities, systematic reviews
suggest similar efficacy (roughly 50% long-term biochemical control) with rates of significant
toxicity (albeit with differing side-effect profiles) [3,4]. Recent propensity-matched analyses of
institutional series suggest comparable efficacy between modalities such as CRYO and salvage
prostatectomy [12]. However, no such comparisons exist between up-front salvage ADT and
local salvage. To address this information gap for men being considered for salvage therapy, we
conducted a propensity-matched analysis between an institutional cohort of men treated with
salvage CRYO and men who proceeded directly to ADT on the randomized PR7 trial [1,7]. We
found that CRYO was associated with a longer OS but similar PCSM compared to up-front
ADT. These findings may be a consequence of differing lengths of follow-up, differences in
patient co-morbidities not controlled for in propensity analysis, or longer exposure to adverse
ADT effects on bone, cardiovascular, metabolic, and cognitive health among the ADT
cohort [2,13].
Our findings have some limitations. For example, important endpoints such as toxicity and
quality of life were not captured, and given the potential morbidity associated with both
systemic and local salvage options, future comparisons incorporating these aspects would be
valuable. We were also limited in the number of variables that were common between the two
databases in terms of propensity matching. In particular, we had no variable reflective of the
relative “fitness” of the two groups, which likely introduced an OS bias in favor of the CRYO
group, similar to bias noted in other retrospective comparisons of prostate cancer therapies
[5]. As with most reports of local salvage interventions, our CRYO group was limited to a single
institution where the necessary expertise had been developed, and our findings may not be
generalizable to other ablative salvage therapies.
Conclusions
Prostate ablation (in this case with whole gland CRYO) was associated with an improved OS but
not PCSM compared to salvage ADT in radio-recurrent prostate cancer. Given the retrospective
nature of our findings, these results should be viewed as hypothesis-generating, and a
randomized control trial comparing these options is necessary to examine potential prostate
cancer-specific and OS differences as well as to examine other important endpoints such as
quality of life and toxicity. Such a trial may need to adopt a pragmatic design where
participating institutions randomize between "local salvage therapy of choice" and salvage
ADT, given the lack of standardized local salvage approaches and the highly specialized nature
of salvage ablative interventions.
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